Micro and nanoparticle drug delivery systems for preventing allotransplant rejection

James D. Fisher, Abhinav P. Acharya, Steven R. Little

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Despite decades of advances in transplant immunology, tissue damage caused by acute allograft rejection remains the primary cause of morbidity and mortality in the transplant recipient. Moreover, the long-term sequelae of lifelong immunosuppression leaves patients at risk for developing a host of other deleterious conditions. Controlled drug delivery using micro- and nanoparticles (MNPs) is an effective way to deliver higher local doses of a given drug to specific tissues and cells while mitigating systemic effects. Herein, we review several descriptions of MNP immunotherapies aimed at prolonging allograft survival. We also discuss developments in the field of biomimetic drug delivery that use MNP constructs to induce and recruit our bodies' own suppressive immune cells. Finally, we comment on the regulatory pathway associated with these drug delivery systems. Collectively, it is our hope the studies described in this review will help to usher in a new era of immunotherapy in organ transplantation.

Original languageEnglish (US)
Pages (from-to)24-35
Number of pages12
JournalClinical Immunology
Volume160
Issue number1
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

    Fingerprint

Keywords

  • Biomaterials
  • Biomimetic
  • Controlled release
  • Microparticles
  • Nanoparticles
  • Transplant immunology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this